Mahneva Olena, Fakhoury Tamara R, Hanspal Sukhwinder Singh, Gonzalez Velazquez Juan O, Patel Nikhil, Henzlova Milena J
Lake Erie College of Osteopathic Medicine, Bradenton, Florida.
Saba University Medical School, Devens, Mississippi ; and.
Clin J Sport Med. 2025 Mar 1;35(2):191-205. doi: 10.1097/JSM.0000000000001320. Epub 2025 Jan 9.
The purpose of this systematic review is to evaluate the original peer-reviewed studies on athletes who developed myocarditis after coronavirus disease (COVID-19) infection or after COVID-19 mRNA vaccination. Both entities likely have an immunologic component. We discuss elite, professional, college, and adolescent athletes. The athletes are generally young and healthy, representing a distinctive population group that differs from the general population. This review includes diagnosis of myocarditis, incidence, complications, prognosis, and return-to-play guidance for sports medicine clinicians and coaches.
We surveyed the PUBMED, Embase, and Web of Science databases for the relevant peer-reviewed articles in the English language published from the onset of the pandemic until April 2023. Included were original observational studies and case series. Excluded were individual case reports and a small series with incomplete data. The resulting search yielded 30 original articles.
Reported myocardial abnormalities in athletes were rare after COVID-19 infection and even less frequent after COVID-19 mRNA vaccination. True incidence, however, may be higher because of under-reporting and frequent asymptomatic presentation. Male gender was prevalent for both manifestations; postvaccination myocarditis occurrence was the highest after the second vaccine dose. Diagnostic and return-to-play algorithms were developed and should be adopted and followed.
The risk of myocarditis from COVID-19 infection and COVID-19 mRNA vaccination is very low. The long-term prognosis and evolution of the observed cardiac magnetic resonance abnormalities are currently unknown. Although inferences can be made from the published data, COVID-19 and postvaccine myocarditis in athletes may represent only a small fraction of the true incidence of those who have been affected worldwide and not evaluated.
本系统评价旨在评估关于冠状病毒病(COVID-19)感染后或COVID-19 mRNA疫苗接种后发生心肌炎的运动员的同行评审原始研究。这两种情况可能都有免疫成分。我们讨论精英、职业、大学和青少年运动员。这些运动员通常年轻且健康,代表了一个与普通人群不同的独特群体。本综述包括心肌炎的诊断、发病率、并发症、预后,以及为运动医学临床医生和教练提供的重返比赛指导。
我们在PUBMED、Embase和科学网数据库中检索了自大流行开始至2023年4月发表的相关英文同行评审文章。纳入的是原始观察性研究和病例系列。排除的是个别病例报告和数据不完整的小系列研究。最终检索得到30篇原始文章。
COVID-19感染后运动员报告的心肌异常很少见,COVID-19 mRNA疫苗接种后更少见。然而,由于报告不足和频繁的无症状表现,实际发病率可能更高。两种表现形式中男性均占主导;接种疫苗后心肌炎在第二剂疫苗接种后发生率最高。已制定诊断和重返比赛算法,应予以采用和遵循。
COVID-19感染和COVID-19 mRNA疫苗接种引起心肌炎的风险非常低。目前尚不清楚观察到的心脏磁共振异常的长期预后和演变情况。尽管可以从已发表的数据中进行推断,但运动员中的COVID-19和疫苗接种后心肌炎可能仅占全球受影响且未接受评估者真实发病率的一小部分。